Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-04-27 |
Resource Citation "179616" Version "1" Updated "2023-11-26 18:54:02+0000"
url: https://fevir.net/resources/Citation/179616
identifier: FEvIR Object Identifier/179616, https://pubmed.ncbi.nlm.nih.gov/26244877
version: 1.0.0-ballot
title: 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
status: active
date: 2024-04-27 20:42:39+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use') | Medline Base (Citation Artifact Classifier#medline-base) |
jurisdiction: World (m49.htm#001)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2015-08-25
lastReviewDate: 2022-12-08
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()
classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)
currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)
statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2015-08-06 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2015-08-06 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2015-08-26 06:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/26244877, mid/NIHMS719565,https://www.ncbi.nlm.nih.gov/pmc//PMC4562797,https://doi.org/10.1056/NEJMoa1503747relatedIdentifier:
https://clinicaltrials.gov/NCT00309985Titles
Type Language Text Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. Abstracts
Text **BACKGROUND:** Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone. **METHODS:** We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. **RESULTS:** A total of 790 patients (median age, 63 years) underwent randomization. After a median follow-up of 28.9 months, the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001). The median time to biochemical, symptomatic, or radiographic progression was 20.2 months in the combination group, as compared with 11.7 months in the ADT-alone group (hazard ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). The rate of a prostate-specific antigen level of less than 0.2 ng per milliliter at 12 months was 27.7% in the combination group versus 16.8% in the ADT-alone group (P<0.001). In the combination group, the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 infection with neutropenia was 2.3%, and the rate of grade 3 sensory neuropathy and of grade 3 motor neuropathy was 0.5%. **CONCLUSIONS:** Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.). relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/12050481/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/12050481relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10801170/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/10801170relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–76.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/12124837/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/12124837relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–25.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23550669/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23550669relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346) J Urol. 2012;188:1164–9.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22921015/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22921015relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818–23.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24258693/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24258693relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470214/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15470214relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470213/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15470213relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26:5936–42.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/19029421/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/19029421relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23306100/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23306100relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/2503724/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/2503724relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9761805/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/9761805relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 2000;92:205–16.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10655437/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/10655437relatesTo
type: cites
citation: Jennison CTB. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci. 1990;5:299–317.
relatesTo
type: cites
citation: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
relatesTo
type: cites
citation: Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/5910392/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/5910392relatesTo
type: cites
citation: Cox D. Analysis of binary data. London: Methuen and Co; 1970.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/21612468/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/21612468relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23228172/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23228172relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Beer TM, strong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24881730/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24881730relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22894553/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22894553relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/20818862/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/20818862relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/20888992/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/20888992relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23863050/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23863050relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol. 2015;67:1028–38.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25301760/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25301760relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: BMJ. 2015;351:h4253
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26251343/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26251343relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Clin Oncol. 2015 Oct;12(10):563
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26305034/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26305034relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Urol. 2015 Dec;12(12):656-8
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26526753/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26526753relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Nat Rev Clin Oncol. 2015 Dec;12(12):687-8
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26552950/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26552950relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: BMC Med. 2015;13:304
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26695172/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26695172relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: J Urol. 2016 Jan;195(1):94
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26699961/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26699961relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: N Engl J Med. 2016 Jan 21;374(3):287
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26789883/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26789883relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: N Engl J Med. 2016 Jan 21;374(3):286
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26789884/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26789884relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2016 Mar;69(3):540
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26867727/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26867727relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2016 Apr;69(4):755-6
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26972499/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26972499relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Eur Urol. 2016 Jan;69(1):178
Documents
Url https://pubmed.ncbi.nlm.nih.gov/27099882/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/27099882relatesTo
type: comment-in
classifier: Comment (#D016420)
citation: Urol Oncol. 2017 Mar;35(3):123
Documents
Url https://pubmed.ncbi.nlm.nih.gov/28159490/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/28159490publicationForm
PublishedIns
Type Identifier Title PublisherLocation Periodical (Published In Type#D020492) Electronic ISSN Type/1533-4406, ISOAbbreviation/N Engl J Med, ISSN Linking/0028-4793, Medline Title Abbreviation/N Engl J Med, NLM Unique ID/0255562 The New England journal of medicine United States citedMedium: Internet (Cited Medium#internet)
volume: 373
issue: 8
articleDate: 2015-08-20
publicationDateText: 2015-Aug-20
language: English (Tags for the Identification of Languages#en)
pageString: 737-46
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2015-08-05
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Antineoplastic Agents (#D000970), Taxoids (#D043823), Docetaxel (chemical-substances#15H5577CQD; #D000077143), Prostate-Specific Antigen (chemical-substances#EC 3.4.21.77; #D017430)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Adult (#D000328)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged, 80 and over (#D000369)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Agents (#D000970)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Therapy, Combination (#D004359)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Follow-Up Studies (#D005500)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Kaplan-Meier Estimate (#D053208)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neutropenia (#D009503)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: chemically induced (#Q000139)
component
component
type: qualifier ()
classifier: epidemiology (#Q000453)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostate-Specific Antigen (#D017430)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: blood (#Q000097)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Journal Article (#D016428), Multicenter Study (#D016448), Randomized Controlled Trial (#D016449), Research Support, N.I.H., Extramural (#D052061), Research Support, Non-U.S. Gov't (#D013485)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
name: Christopher J Sweeney
forenameInitials: CJ
affiliation: : From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).
entry
name: Yu-Hui Chen
forenameInitials: YH
entry
name: Michael Carducci
forenameInitials: M
entry
name: Glenn Liu
forenameInitials: G
entry
name: David F Jarrard
forenameInitials: DF
entry
name: Mario Eisenberger
forenameInitials: M
entry
name: Yu-Ning Wong
forenameInitials: YN
entry
name: Noah Hahn
forenameInitials: N
entry
name: Manish Kohli
forenameInitials: M
entry
name: Matthew M Cooney
forenameInitials: MM
entry
name: Robert Dreicer
forenameInitials: R
entry
name: Nicholas J Vogelzang
forenameInitials: NJ
entry
name: Joel Picus
forenameInitials: J
entry
name: Daniel Shevrin
forenameInitials: D
entry
name: Maha Hussain
forenameInitials: M
entry
name: Jorge A Garcia
forenameInitials: JA
entry
name: Robert S DiPaola
forenameInitials: RS
Generated Narrative: Practitioner #author0
name: Christopher J Sweeney
Generated Narrative: Practitioner #author1
name: Yu-Hui Chen
Generated Narrative: Practitioner #author2
name: Michael Carducci
Generated Narrative: Practitioner #author3
name: Glenn Liu
Generated Narrative: Practitioner #author4
name: David F Jarrard
Generated Narrative: Practitioner #author5
name: Mario Eisenberger
Generated Narrative: Practitioner #author6
name: Yu-Ning Wong
Generated Narrative: Practitioner #author7
name: Noah Hahn
Generated Narrative: Practitioner #author8
name: Manish Kohli
Generated Narrative: Practitioner #author9
name: Matthew M Cooney
Generated Narrative: Practitioner #author10
name: Robert Dreicer
Generated Narrative: Practitioner #author11
name: Nicholas J Vogelzang
Generated Narrative: Practitioner #author12
name: Joel Picus
Generated Narrative: Practitioner #author13
name: Daniel Shevrin
Generated Narrative: Practitioner #author14
name: Maha Hussain
Generated Narrative: Practitioner #author15
name: Jorge A Garcia
Generated Narrative: Practitioner #author16
name: Robert S DiPaola
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Adult (#D000328)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged, 80 and over (#D000369)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Agents (#D000970)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Drug Therapy, Combination (#D004359)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Follow-Up Studies (#D005500)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Kaplan-Meier Estimate (#D053208)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Neutropenia (#D009503)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: chemically induced (#Q000139)
component
component
type: qualifier ()
classifier: epidemiology (#Q000453)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostate-Specific Antigen (#D017430)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: blood (#Q000097)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: adverse effects (#Q000009)
component
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-04-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change